Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00747253 · ClinicalTrials.gov registry record · Phase 1
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
A Phase 1 study of Glioblastoma Multiforme and Brain Tumor, sponsored by Monteris Medical.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT00747253: Completed Phase 1 study of Glioblastoma Multiforme and Brain Tumor, sponsored by Monteris Medical.
NCT00747253 is a Phase 1 study of Glioblastoma Multiforme and Brain Tumor that has completed, run by Monteris Medical. The registered enrollment target is 10 participants, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00747253, a Phase 1 study of Glioblastoma Multiforme and Brain Tumor, has completed, sponsored by Monteris Medical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).
Conditions Studied
Interventions
- DEVICE AutoLITT system
Study Locations (2)
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- Cleveland Clinic Foundation, 9500 Euclid Ave - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
What the finished NCT00747253 record still lists
NCT00747253 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 97-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (90% lower).
The record links to 6 conditions, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which AutoLITT system is the first listed.
NCT00747253 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00747253 about?
NCT00747253 is a clinical study titled "Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors". The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).
What is the current status of trial NCT00747253?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2008-08. Estimated completion is 2010-04.
What conditions does trial NCT00747253 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme, Brain Tumor, Brain Cancer, Brain Neoplasm, Recurrent Glioblastoma Multiforme.
What interventions are being tested in trial NCT00747253?
The interventions under investigation include: AutoLITT system (DEVICE).
Who is sponsoring clinical trial NCT00747253?
This trial is sponsored by Monteris Medical, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00747253 being conducted?
This trial has 2 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00747253's enrollment target sits among peer trials
10 82nd of 88 higher than 4 of 88 other Glioblastoma Multiforme trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma Multiforme trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RECRUITING · Phase 1
-
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
RECRUITING · Phase 1
-
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia